abstract |
The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-IL4R antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interleukin-4 receptor alpha (hIL-4Rα), about 50 mM to about 400 mM of a viscosity modifier; about 0.002% to about 0.2% of a non-ionic surfactant; and a formulation buffer. In some embodiments, the formulation buffer is essentially free of phosphate. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation. |